Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 11;371(11):1005-15.
doi: 10.1056/NEJMoa1403088.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

Kathryn G Roberts  1 , Yongjin Li, Debbie Payne-Turner, Richard C Harvey, Yung-Li Yang, Deqing Pei, Kelly McCastlain, Li Ding, Charles Lu, Guangchun Song, Jing Ma, Jared Becksfort, Michael Rusch, Shann-Ching Chen, John Easton, Jinjun Cheng, Kristy Boggs, Natalia Santiago-Morales, Ilaria Iacobucci, Robert S Fulton, Ji Wen, Marcus Valentine, Cheng Cheng, Steven W Paugh, Meenakshi Devidas, I-Ming Chen, Shalini Reshmi, Amy Smith, Erin Hedlund, Pankaj Gupta, Panduka Nagahawatte, Gang Wu, Xiang Chen, Donald Yergeau, Bhavin Vadodaria, Heather Mulder, Naomi J Winick, Eric C Larsen, William L Carroll, Nyla A Heerema, Andrew J Carroll, Guy Grayson, Sarah K Tasian, Andrew S Moore, Frank Keller, Melissa Frei-Jones, James A Whitlock, Elizabeth A Raetz, Deborah L White, Timothy P Hughes, Jaime M Guidry Auvil, Malcolm A Smith, Guido Marcucci, Clara D Bloomfield, Krzysztof Mrózek, Jessica Kohlschmidt, Wendy Stock, Steven M Kornblau, Marina Konopleva, Elisabeth Paietta, Ching-Hon Pui, Sima Jeha, Mary V Relling, William E Evans, Daniela S Gerhard, Julie M Gastier-Foster, Elaine Mardis, Richard K Wilson, Mignon L Loh, James R Downing, Stephen P Hunger, Cheryl L Willman, Jinghui Zhang, Charles G Mullighan
Affiliations

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

Kathryn G Roberts et al. N Engl J Med. .

Abstract

Background: Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profile similar to that of BCR-ABL1-positive ALL, alterations of lymphoid transcription factor genes, and a poor outcome. The frequency and spectrum of genetic alterations in Ph-like ALL and its responsiveness to tyrosine kinase inhibition are undefined, especially in adolescents and adults.

Methods: We performed genomic profiling of 1725 patients with precursor B-cell ALL and detailed genomic analysis of 154 patients with Ph-like ALL. We examined the functional effects of fusion proteins and the efficacy of tyrosine kinase inhibitors in mouse pre-B cells and xenografts of human Ph-like ALL.

Results: Ph-like ALL increased in frequency from 10% among children with standard-risk ALL to 27% among young adults with ALL and was associated with a poor outcome. Kinase-activating alterations were identified in 91% of patients with Ph-like ALL; rearrangements involving ABL1, ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, PTK2B, TSLP, or TYK2 and sequence mutations involving FLT3, IL7R, or SH2B3 were most common. Expression of ABL1, ABL2, CSF1R, JAK2, and PDGFRB fusions resulted in cytokine-independent proliferation and activation of phosphorylated STAT5. Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6-NTRK3 fusion was sensitive to crizotinib.

Conclusions: Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine kinase inhibitors. Trials identifying Ph-like ALL are needed to assess whether adding tyrosine kinase inhibitors to current therapy will improve the survival of patients with this type of leukemia. (Funded by the American Lebanese Syrian Associated Charities and others.).

PubMed Disclaimer

Figures

Figure 1
Figure 1. Kaplan–Meier Estimates of Event-free and Overall Survival among Patients with Philadelphia Chromosome–like Acute Lymphoblastic Leukemia (Ph-like ALL)
Panel A shows the median (±SD) rates of event-free survival for young adults, adolescents, and high-risk children with Ph-like ALL (24.1±10.5%, 41.0±7.4%, and 58.2±5.3%, respectively). Panel B shows rates of overall survival in the three age groups (25.8±9.9%, 65.8±7.1%, and 72.8±4.8%, respectively).
Figure 2
Figure 2. Recurring Kinase Alterations in Ph-like ALL
Data are shown for 154 patients with Ph-like ALL who underwent detailed genomic analysis, including transcriptome sequencing (RNA-seq), whole-genome sequencing (WGS), whole-exome sequencing (WES), and reverse-transcriptase polymerase chain reaction (RT-PCR). The cohort is divided into patients with ABL-class fusions (ABL1, ABL2, CSF1R, PDGFRB) responsive to dasatinib, EPOR or JAK2 rearrangements, CRLF2 rearrangements, other JAK–STAT–activating mutations (IL7R, FLT3, SH2B3, JAK1, JAK3, TYK2, IL2RB, and TSLP), other kinase fusions (miscellaneous group, including NTRK3 and DGKH), alterations in the Ras pathway (KRAS, NRAS, PTPN11, NF1, and BRAF), and no kinase alteration. For details of specific alterations, see Tables S9 and S12 in Supplementary Appendix 1 and Table S20 in Supplementary Appendix 3.
Figure 3
Figure 3. Response to Tyrosine Kinase Inhibitors
Panel A shows the proliferation of interleukin-7–dependent primary Arf−/− pre-B cells expressing the dominant negative Ikaros isoform (Ik6) with empty vector, RCSD1–ABL1, RCSD1–ABL2, SSBP2–CSF1R, or PAX5–JAK2 in the absence of cytokine. Panel B shows the growth of Arf−/− pre-B cells in increasing concentrations of dasatinib. Panel C shows constitutive phosphorylation of STAT5 and CRKL (pSTAT5 and pCRKL, respectively). Cells expressing ABL2, CSF1R, and JAK2 fusions have enhanced STAT5 activation, which is inhibited by dasatinib in RCSD1–ABL2 and SSBP2–CSF1R and by ruxolitinib in PAX5–JAK2.
See this image and copyright information in PMC

Comment in

Similar articles

  • Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
    Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Gu Z, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ 3rd, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP. Reshmi SC, et al. Blood. 2017 Jun 22;129(25):3352-3361. doi: 10.1182/blood-2016-12-758979. Epub 2017 Apr 13. Blood. 2017. PMID: 28408464 Free PMC article. Clinical Trial.
  • Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
    Roberts KG, Reshmi SC, Harvey RC, Chen IM, Patel K, Stonerock E, Jenkins H, Dai Y, Valentine M, Gu Z, Zhao Y, Zhang J, Payne-Turner D, Devidas M, Heerema NA, Carroll AJ, Raetz EA, Borowitz MJ, Wood BL, Mattano LA Jr, Maloney KW, Carroll WL, Loh ML, Willman CL, Gastier-Foster JM, Mullighan CG, Hunger SP. Roberts KG, et al. Blood. 2018 Aug 23;132(8):815-824. doi: 10.1182/blood-2018-04-841676. Epub 2018 Jul 11. Blood. 2018. PMID: 29997224 Free PMC article. Clinical Trial.
  • Philadelphia chromosome-like acute lymphoblastic leukemia.
    Tasian SK, Loh ML, Hunger SP. Tasian SK, et al. Blood. 2017 Nov 9;130(19):2064-2072. doi: 10.1182/blood-2017-06-743252. Epub 2017 Oct 2. Blood. 2017. PMID: 28972016 Free PMC article. Review.
  • Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
    Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG. Roberts KG, et al. Cancer Cell. 2012 Aug 14;22(2):153-66. doi: 10.1016/j.ccr.2012.06.005. Cancer Cell. 2012. PMID: 22897847 Free PMC article.
  • BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
    Boer JM, den Boer ML. Boer JM, et al. Eur J Cancer. 2017 Sep;82:203-218. doi: 10.1016/j.ejca.2017.06.012. Epub 2017 Jul 12. Eur J Cancer. 2017. PMID: 28709134 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–55. - PMC - PubMed
    1. Mullighan CG. Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50:314–24. - PMC - PubMed
    1. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:21–9. - PubMed
    1. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–80. - PMC - PubMed
    1. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125–34. - PMC - PubMed

Publication types

MeSH terms

-